Overview
Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery
Status:
Unknown status
Unknown status
Trial end date:
2019-04-30
2019-04-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
Vasoplegic syndrome is a common complication after cardiac surgery. Low dose vasopressin can up-regulate blood pressure and improve clinical outcomes compared with norepinephrine (mainly acute kidney injury Anesthesiology 2017; 126:85-93). Pituitrin is used as a substitute for vasopressin in our center, which contains both vasopressin and oxytocin. Oxytocin may alleviate inflammatory process-associated kidney injury (Peptides 2006;27:2249-57). Therefore, the investigators hypothesize Pituitrin may be preferable to norepinephrine in the renal protection of patients with vasoplegic syndrome after cardiac surgery. Moreover, the serum levels of vasopressin, catecholamine, corticosteroid and corticotropin-releasing hormone will be measured.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Beijing Anzhen HospitalTreatments:
Benzocaine
Norepinephrine
Criteria
Inclusion Criteria:1. Patients diagnosed as vasoplegic syndrome(defined as mean arterial pressure less than 65
mmHg resistant to fluid challenge and cardiac index greater than 2.2 L/min ยท m2) within 24
hours after cardiac surgery.
Exclusion Criteria:
1. Age < 18 and > 75 years.
2. Received renal replacement therapy before cardiac surgery.
3. Diagnosed as endocrine disease before cardiac surgery.
4. Diagnosed as sever peripheral vascular disease before cardiac surgery.
5. Extracorporeal membrane oxygenation support before admission.
6. To receive heart transplantation.
7. Infection on admission.
8. Pregnant or maternal patients.
9. Refusal of consent